2023
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review
Majem M, Basch E, Cella D, Garon E, Herbst R, Leighl N. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. Lung Cancer 2023, 187: 107419. PMID: 38070301, DOI: 10.1016/j.lungcan.2023.107419.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage diseaseHealth-related qualityClinical trialsEarly-stage non-small cell lung cancerTreatment-related adverse effectsAppropriate HRQoL instrumentNSCLC clinical trialsCell lung cancerLong-term treatmentLung cancer clinical trialsCancer clinical researchCancer clinical trialsAdjuvant treatmentAdvanced diseaseHRQOL assessmentTreatment landscapeDisease recurrenceHRQoL instrumentsLung cancerDisease progressionLife measuresHRQoLNarrative reviewHealthcare professionals
2020
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman J, Kim S, Marmol D, Rukazenkov Y, Wu Y. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Journal Of Clinical Oncology 2020, 38: lba5-lba5. DOI: 10.1200/jco.2020.38.18_suppl.lba5.Peer-Reviewed Original ResearchDisease-free survivalComplete tumor resectionDFS hazard ratioAdjuvant chemotherapyData cutoffHazard ratioOverall survivalTumor resectionAdjuvant osimertinibDFS ratesEGFRm NSCLCEGFR-TKISafety profileEGFR mutation-positive NSCLCEffective new treatment strategyResected stage IISafety of osimertinibEarly-stage diseaseMutation-positive NSCLCNew treatment strategiesUnplanned interim analysisEligible ptsIIIA NSCLCNSCLC presentPS 0/1Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal Of Thoracic Oncology 2020, 15: 914-947. PMID: 32179179, DOI: 10.1016/j.jtho.2020.03.006.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsThoracic malignanciesCheckpoint inhibitorsThymic carcinomaDeath ligand 1 (PD-L1) immune checkpoint inhibitorsAnti-programmed cell death protein 1Cell death protein 1/T-lymphocyte antigen 4 antibodyCombination of ICIsDeath protein 1/Long-term survival benefitHost antitumor immune responseCell death protein 1Immune evasion processStage III NSCLCAntitumor immune responseEarly-stage diseaseDeath protein 1Portion of patientsMalignant pleural mesotheliomaOptimal treatment durationFuture treatment strategiesDefinitive clinical benefitFuture therapeutic developmentAvailable scientific evidence
2015
Targeted Therapy in Solid Tumors: Lung Cancer
Waqar S, Morgensztern D, Herbst R. Targeted Therapy in Solid Tumors: Lung Cancer. 2015, 224-230. DOI: 10.1002/9781118468678.ch23.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerManagement of NSCLCMetastatic non-small cell lung cancerChoice of regimensUnprecedented response ratesProgression-free survivalEarly-stage diseaseIncurable metastatic diseaseCell lung cancerImproved cure ratesToxic treatment optionsMetastatic diseaseStage diseaseCure rateTreatment optionsTargeted therapyToxicity profileSecondary resistanceResponse rateSolid tumorsPatientsTumor progressionTherapyTumors
2011
Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years
Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, Bonner JA. Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years. Clinical Lung Cancer 2011, 13: 115-122. PMID: 22000695, DOI: 10.1016/j.cllc.2011.05.008.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerNational Cancer Data BaseExtensive SCLCHazard ratioLimited SCLCRadiation therapyExtensive small cell lung cancerLimited small cell lung cancerNon-Hispanic white patientsBenefit of chemotherapyReceipt of surgeryAmerican Joint CommitteeEarly-stage diseaseMedian survivalOnly chemotherapyStage diseasePrognostic factorsWhite patientsFemale patientsImproved survivalFemale sexLung cancerCancer stageBetter survivalPatients
2001
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
Tseng J, Glisson B, Khuri F, Shin D, Myers J, El‐Naggar A, Roach J, Ginsberg L, Thall P, Wang X, Teddy S, Lawhorn K, Zentgraf R, Steinhaus G, Pluda J, Abbruzzese J, Hong W, Herbst R. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001, 92: 2364-2373. PMID: 11745292, DOI: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsMetastatic squamous cell carcinomaSquamous cell carcinomaPhase II studyCell carcinomaProgressive diseaseII studySurvival timeAntiangiogenic effectsAdvanced squamous cell carcinomaBasic fibroblast growth factor levelsMedian overall survival timeFibroblast growth factor levelsSingle-agent thalidomideSingle-agent antitumor activityEarly-stage diseasePopulation of patientsOverall survival timeGrowth factor levelsVascular endothelial growth factorMinimal residual diseaseSignificant antitumor effectEndothelial growth factorMechanism of actionStage diseaseUnacceptable toxicity